Evaluation of Clinical Progression in Patients With Motor Predominant Parkinson Disease.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

3 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-14

Study Completion Date

2021-04-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is the longitudinal prospective clinical evaluation in patients with motor predominant PD; it will assess the individual disease progression (change) of the clinical and imaging parameters measured at 6-month interval over a minimum of 12 months.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The absence of clear PD subtypes defining a common path and rate of disease progression, combined with the absence of validated biomarkers indicative of disease progression and a strong placebo effect, constitute a challenge for clinical trials assessing new potential disease-modifying therapies in PD.

The present cohort would constitute a well-defined population of patients, with individual progression assessment, suitable to evaluate new disease-modifying therapies in a subsequent Phase1/2 clinical trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Idiopathic Parkinson's Disease (According to British Brain Bank Criteria); genetic forms of PD are not excluded
2. Male or female adult, aged 70 or less
3. Modified Hoehn and Yahr stage 2 to 3 in OFF state
4. Disease duration, i.e. time from first motor symptoms between 2 to 8 (included) years ; first motor symptoms to be taken into consideration being the cardinal motor symptoms of PD (bradykinesia, tremor and rigidity)
5. Univoqual response to L-DOPA (of at least 50% in MDS-UPDRS Part III motor score)
6. Presence of fluctuations and/or dyskinesia
7. MDS-UPDRS total motor score ≥15 in OFF state
8. L-Dopa treatment stable for at least 4 weeks
9. Covered by healthcare insurance
10. Written informed consent form signed

Exclusion Criteria

1. Scan Without Evidence of Dopamine Deficit (SWEDD) (DaTSCAN)
2. Atypical parkinsonism syndrome
3. Dementia as detected by a score \< 21/30 at the Montreal Cognitive Assessment Screening (MoCA)
4. Psychiatric disorders including major depression with suicidal thoughts as evaluated by a psychiatrist or a neurologist at the selection period
5. Any medical or psychological problems which may interfere with a smooth conduction of the study protocol (e.g. cancer with a limited life expectancy)
6. History of significant brain or vascular disease (tumor, epilepsy, stroke …)
7. Any contraindication for undergoing MRI of the head
8. Prior brain surgical procedures with or without implementation of an intra-cerebral device
9. Drug or alcohol addiction
10. Pregnancy or breastfeeding
11. Patient with reproductive potential who do not agree to use an accepted effective method of contraception - investigator's judgment- during the study period
12. Illiteracy or insufficient language skills (French) to complete the questionnaires
13. Patient deprived of liberty by a judicial or administrative decision, or who is under a measure of legal protection (e.g. guardianship or curatorship).
14. Simultaneous participation in another clinical trial with the administration of investigational drug(s)

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital Henri Mondor

Créteil, , France

Site Status

Hôpital Pitié-Salpétrière

Paris, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BREN01_CLIN_001

Identifier Type: -

Identifier Source: org_study_id